The global sepsis diagnostics market size was valued at over USD 502.0 million in 2018 and is expected to witness a CAGR of 9.8% over the forecast period. Rising prevalence of sepsis has led to a growing need for its early diagnosis. Septic poisoning may result in severe inflammation, leading to prolonged hospitalization. This condition is also one of the leading causes of death. Hence, in order to reduce the alarming mortality rate amongst people developing septicemia, demand for related diagnostic products is expected to grow to a great extent in near future.
Hospital-acquired infections also significantly contribute to the growth of the market. Such infections are a result of prolonged hospital stays. The World Health Organization (WHO) estimated that the rate of ICU-acquired infections is at least 2-3 times higher in developing countries as compared to developed countries. These infections including urinary-tract and surgical site wound infections that majorly lead to severe sepsis.
Increasing number of surgical cases leading to post-operative infections cause septic shock. Post-surgical infections generally arise due to factors such as failure to sterilize the surgical site and surgical instruments. Thus, diagnostic instruments and assays are increasingly demanded by hospitals for early detection of septic shock.
Hospital-acquired infections are on the rise, owing to the high prevalence of numerous chronic diseases such as diabetes. Rising number of hospital admissions in acute care hospitals often lead to infections, which cause sepsis. According to the WHO, 7 out of every 100 hospitalized patients will develop hospital-acquired infections in developed countries, whereas, the number will increase to 10 in developing countries, due to poor healthcare infrastructure. The WHO also estimated that the rate of ICU-acquired infections is at least two to three times higher in developing countries as compared to developed nations. These facts are indicative of the rising demand for sepsis diagnostic products globally.
Microbiology held the leading market share in 2018, primarily due to the fact that it allows the quantitative detection and identification of microorganisms for sepsis diagnosis through the application of culture media tests.
Molecular diagnostics is anticipated to showcase attractive growth over the forecast period. Factors attributed to the growth are low turnaround time and accurate results. Such molecular diagnostic methods allow reduced hospital stays and also aid in diminishing mortality rate.
The laboratory segment dominated the market in 2018 owing to the rising number of blood culture tests being conducted in laboratories. However, laboratory testing leads to delay in delivering the diagnostic results, which may affect the initiation of treatment.
Point-of-Care (PoC) testing is expected to witness healthy growth over the forecast period. Introduction of technologically advanced products and increasing demand for rapid diagnostic tests are expected to support market growth.
On the basis of pathogens causing septicemia, the market has been segmented into bacterial, fungal sepsis, and other viruses and parasites. Bacterial sepsis segment held the largest market share in 2018 due to the fact that most of the patients suffering from blood poisoning disease are victims of bacterial infection. The most commonly formed bacterial sepsis is gram-negative bacteria.
Fungal sepsis is projected to expand at a attractive CAGR due to the prevalence of Candida infection resulting in septic poisoning. A lesser number of viruses and parasites cause this disease, hence, this segment accounted for a very low share in 2018.
On the basis of product, the sepsis diagnostics market is segmented into instruments, blood culture media, assay kits and reagents, and software. In 2018, blood culture media was estimated to be the largest grossing segment and is also anticipated to be fastest growing during the forecast period. This is due to the fact that blood culture is considered as the gold standard method and cost-effective mode of testing by clinicians.
Assay kits and reagents are also expected to showcase lucrative growth owing to their capability of early diagnosis as well as introduction of automated tests by major companies. On the other hand, instruments and software accounted for the smallest market share in 2018. High cost of automated instruments may hinder the growth to an extent as many laboratories with budget constraints are likely to opt for conventional methods used for pathogen identification.
In 2018, North America led the market owing to the presence of a well-established healthcare infrastructure as well as the rapid adoption of advanced products. Moreover, septic poisoning is a leading cause of mortality in countries like U.S., which is accelerating the demand for diagnostic products.
Asia Pacific is projected to exhibit lucrative CAGR over the forecast period. This region provides immense opportunities for key players through the introduction of novel sepsis diagnostic tests to reduce the increasing mortality rate.
Some of the key market players are Becton, Dickinson and Company; bioMérieux SA; Roche Diagnostics; Beckman Coulter, Inc.; Thermo Fisher Scientific, Inc.; Cepheid Inc.; Bruker Corporation; and Nanosphere, Inc.
The major companies are undertaking strategies such as mergers and acquisitions, new product development, and regional expansion to cater to the unmet needs of the patients. For instance, in 2016, BioFire Diagnostics, LLC,-the molecular biology counterpart of bioMérieux-received the U.S. Food and Drug Administration (FDA) clearance for FilmArray Torch for use with the FilmArray Blood Culture Identification (BCID) Panel.
Base year for estimation
Actual estimates/Historical data
2014 - 2017
2019 - 2026
Revenue in USD Million & CAGR from 2019 to 2026
North America, Europe, Asia Pacific, Latin America & MEA
U.S., Canada, U.K., Germany, Spain, France, Italy, Russia, Japan, India, China, South Korea, Singapore, Australia, Brazil, Mexico, Argentina, South Africa, Saudi Arabia, UAE
Revenue forecast, company share, competitive landscape, growth factors and trends
15% free customization scope (equivalent to 5 analyst working days)
If you need specific information, which is not currently within the scope of the report, we will provide it to you as a part of customization
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2014 to 2026. For the purpose of this study, Grand View Research has segmented the global sepsis diagnostics market report on the basis of product, technology, pathogen, testing type, and region:
Product Outlook (Revenue, USD Million, 2014 - 2026)
Blood Culture Media
Assay Kits and Reagents
Technology Outlook (Revenue, USD Million, 2014 - 2026)
Pathogen Outlook (Revenue, USD Million, 2014 - 2026)
Testing Type Outlook (Revenue, USD Million, 2014 - 2026)
Regional Outlook (Revenue, USD Million, 2014 - 2026)
Avail customized purchase options to meet your exact research needs:
Get your queries resolved from an industry expert.
Design an exclusive study to serve your research needs.
A testimonial for service in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.
"The quality of research they have done for us has been excellent..."